List of Excipients in Branded Drug DOXERCALCIFEROL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hospira Inc	DOXERCALCIFEROL	doxercalciferol	0409-1331	ALCOHOL
Hospira Inc	DOXERCALCIFEROL	doxercalciferol	0409-1331	BUTYLATED HYDROXYTOLUENE
Hospira Inc	DOXERCALCIFEROL	doxercalciferol	0409-1331	EDETATE DISODIUM

Generic Drugs Containing DOXERCALCIFEROL

Company	Ingredient	NDC	Excipient
West-Ward Pharmaceuticals Corp	doxercalciferol	0054-0338	ALCOHOL
West-Ward Pharmaceuticals Corp	doxercalciferol	0054-0338	AMMONIA
West-Ward Pharmaceuticals Corp	doxercalciferol	0054-0338	BUTYL ALCOHOL

What are the Most Frequently-Used Excipients in DOXERCALCIFEROL?

# Of NDCs	Excipient
14	ALCOHOL
2	AMMONIA
1	BUTYL ALCOHOL

Doxercalciferol Excipient Strategy and Commercial Opportunities

Last updated: September 4, 2026

Doxercalciferol is a small-molecule vitamin D analog used primarily to control secondary hyperparathyroidism in chronic kidney disease. Its commercial opportunity is concentrated in generic oral capsules, dialysis-centered injectable products, and differentiated formulations that improve dose uniformity, stability, administration, or supply reliability. Biosimilar competition is irrelevant because doxercalciferol is not a biologic. The main barriers are low dose strength, vitamin D analog stability, narrow therapeutic dosing, regulatory equivalence, and limited market size.

What is doxercalciferol and how is it marketed?

Doxercalciferol is a synthetic vitamin D2 analog and prodrug. It is converted in the liver to 1-alpha,25-dihydroxyvitamin D2, an active metabolite that suppresses parathyroid hormone production. The drug is indicated for secondary hyperparathyroidism in patients with chronic kidney disease, including patients receiving dialysis.[1]

The U.S. reference product was Hectorol, marketed in oral capsules and an intravenous injectable presentation. U.S. generic doxercalciferol products have entered the market through the abbreviated new drug application pathway.

Attribute	Doxercalciferol
Active ingredient	Doxercalciferol
Pharmacologic class	Vitamin D analog
Primary use	Secondary hyperparathyroidism associated with chronic kidney disease
Oral strengths	Commonly 0.5 mcg, 1 mcg and 2.5 mcg capsules
Injectable strength	Commonly 4 mcg/mL
Primary customers	Nephrologists, dialysis providers, hospitals and specialty pharmacies
FDA pathway for generics	ANDA
Biosimilar pathway	Not applicable
Main formulation issue	Accurate delivery of microgram quantities with chemical and physical stability
Main commercial risk	Small, mature market with substitution and reimbursement pressure

The oral product is generally used in chronic outpatient treatment. The injectable product is associated with dialysis and institutional administration, where procurement, storage, administration workflow and contract pricing influence market share.

What excipients are used in doxercalciferol products?

Doxercalciferol products use conventional solid-dose and sterile-injection excipient systems. The exact composition varies by manufacturer and dosage form and must be taken from the applicable FDA labeling and product-specific inactive-ingredient disclosures.[1,2]

Oral capsule excipients

Commercial capsule formulations typically require:

• A diluent, such as lactose or microcrystalline cellulose, to provide capsule fill volume.
• A disintegrant, such as sodium starch glycolate or croscarmellose sodium.
• A lubricant, commonly magnesium stearate.
• Capsule-shell gelatin or a vegetarian shell alternative.
• Colorants or opacifiers for product identification and light protection.
• Process controls that prevent segregation of the low-dose active ingredient.

The low amount of doxercalciferol creates a content-uniformity challenge. At a 0.5 mcg strength, the active ingredient may represent a very small fraction of total capsule fill. Direct blending can produce assay variability unless the manufacturer uses geometric dilution, ordered blending, spray layering, a premix, or another validated distribution process.

The excipient system should therefore be selected for blend uniformity rather than simply low cost. Key variables include particle-size distribution, density, electrostatic behavior, moisture content and lubricant sensitivity.

Injectable excipients

The injectable product requires a sterile, clear or substantially clear solution with appropriate pH, osmolality, container compatibility and microbiological control. The reference injectable formulation uses a solvent and surfactant system appropriate for a poorly water-soluble vitamin D analog.[1]

Potential functions of the injectable excipient system include:

• Solubilization of doxercalciferol.
• Prevention of precipitation during storage and dilution.
• Control of adsorption to glass, elastomer or plastic contact surfaces.
• Protection from oxidation and light.
• Maintenance of sterility and acceptable particulate levels.
• Compatibility with dialysis-center preparation and administration practices.

The commercial developer must assess extractables and leachables, stopper compatibility, adsorption, photostability and in-use stability. These issues are more material for an injectable than for a conventional oral capsule.

What excipient strategies can improve doxercalciferol products?

The strongest formulation opportunities are incremental. A new excipient alone is unlikely to create durable market exclusivity, but an excipient system that solves a measurable performance problem can support a differentiated product or improve manufacturing economics.

How can excipients improve oral capsule manufacturing?

A robust oral formulation strategy should focus on the following:

Development objective	Relevant excipient or process approach	Commercial benefit
Improve content uniformity	Ordered blending, premix concentrate, spray layering or high-shear blending	Reduces assay failure and batch rejection
Improve flow	Microcrystalline cellulose, silicified cellulose or controlled particle-size diluents	Supports high-speed encapsulation
Improve disintegration	Sodium starch glycolate or croscarmellose sodium	Reduces release variability
Reduce segregation	Matched density and particle-size excipients	Improves dose consistency
Improve light protection	Opaque capsule shell and protective packaging	Extends stability
Reduce oxidation risk	Low-moisture excipients and oxygen-controlled packaging	Protects potency
Support dietary or religious preferences	Hypromellose capsule shell	Expands patient and procurement eligibility
Reduce supply risk	Dual-source excipient qualification	Improves manufacturing continuity

A premix or coated-particle approach may have the greatest technical value where the active ingredient is difficult to distribute uniformly. The approach must still demonstrate equivalent dissolution and bioavailability, and it can increase process complexity.

Can a softgel or lipid formulation create a commercial opportunity?

A softgel or lipid-based formulation could improve solubilization and reduce powder-handling issues. The opportunity is limited by the need to demonstrate bioequivalence against a low-dose capsule and to control fill-weight, shell compatibility, leakage and long-term stability.

A lipid formulation is more attractive if it delivers one of four measurable advantages:

1. Better chemical stability.
2. Lower dose variability.
3. Improved manufacturing yield.
4. A meaningful administration or adherence benefit.

Without one of these advantages, a softgel would likely compete primarily on price and would face a difficult return on development spending.

Is an oral solution commercially attractive?

An oral solution could serve patients who cannot swallow capsules and could support flexible dose titration. Its development challenges include:

• Low-dose measurement accuracy.
• Solubility at the target concentration.
• Adsorption to dosing devices.
• Preservative effectiveness.
• Container closure compatibility.
• Photostability.
• Potential dosing errors in home use.

The formulation would need a calibrated oral syringe and clear concentration labeling. A solution may qualify as a differentiated product, but the addressable market is narrower than the standard capsule market.

What formulation patents protect doxercalciferol products?

The original doxercalciferol composition and product patents are old relative to the current generic market. Public FDA product information and Orange Book records should be used to confirm any active listed patents for a specific reference product and jurisdiction.[2,3]

What is the Orange Book status of doxercalciferol?

The Orange Book records approved reference products, therapeutic-equivalence information and, where applicable, listed patents and exclusivity. Doxercalciferol is a small molecule and is therefore evaluated through the ANDA framework rather than the biosimilar framework.[2]

For commercial diligence, the relevant questions are:

• Whether the specific reference product has active Orange Book-listed patents.
• Whether those patents cover the active ingredient, dosage form, formulation or method of use.
• Whether a generic applicant has submitted a Paragraph IV certification.
• Whether any listed patent has been delisted, expired or removed.
• Whether the generic product is therapeutically equivalent to the reference product.

The practical IP position is likely more favorable for generic entry than for innovative reformulation. A new formulation could obtain patents on composition, excipient ratios, particle engineering, packaging, stability or manufacturing steps. Such patents would not necessarily block a conventional capsule that uses a different formulation.

What patent claims could support a new doxercalciferol product?

Potential claim categories include:

• A stable low-dose solid composition.
• A doxercalciferol premix with defined particle-size or concentration limits.
• A controlled-release formulation.
• A liquid formulation with specified solvent, surfactant and antioxidant concentrations.
• A sterile injectable solution with improved dilution stability.
• A light-protective container system.
• A manufacturing process that produces defined content uniformity.
• A method of treating a narrowly defined chronic kidney disease population.

Method-of-use patents face substantial enforceability and infringement challenges because physicians, dialysis providers and pharmacies may control treatment decisions. Composition and manufacturing claims are generally easier to monitor than treatment-method claims, although their scope depends on claim drafting and product testing.

When does doxercalciferol lose exclusivity?

Doxercalciferol’s original market exclusivity is long past. The commercial question is not loss of first-entry exclusivity but the remaining scope of any enforceable patent rights attached to a particular product or newly developed formulation.

Exclusivity category	Relevance to doxercalciferol
New chemical entity exclusivity	Historical only; expired
Orphan-drug exclusivity	Not generally the core protection for this product
Pediatric exclusivity	Must be checked against the specific FDA record
Orange Book patent protection	Product- and patent-specific
Formulation patent protection	Possible for new products
Manufacturing patent protection	Possible but generally narrower
Biosimilar exclusivity	Not applicable
Generic first-filer exclusivity	Possible if an ANDA qualifies under the Hatch-Waxman framework

A company entering with a conventional capsule should expect competition from approved generic products rather than reliance on an unexpired innovator exclusivity period.

What Paragraph IV challenges affect doxercalciferol?

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or not infringed. Such certifications can trigger patent litigation and a potential 30-month stay of FDA approval under the Hatch-Waxman statute, subject to the statutory conditions.[4]

For doxercalciferol, Paragraph IV risk is most relevant when:

• A reference product has an unexpired listed patent.
• A generic applicant seeks approval before the patent expiration date.
• A new formulation creates its own patent estate.
• The generic applicant uses a noninfringing formulation while challenging a method-of-use or formulation patent.

The mature age of doxercalciferol reduces the likelihood that a basic active-ingredient patent will remain commercially significant. The more credible barriers are product-specific formulation claims and manufacturing know-how that may not appear in the Orange Book.

Which companies are challenging or competing with doxercalciferol?

Competition comes from three groups:

1. Generic doxercalciferol manufacturers.
2. Alternative vitamin D analog products.
3. Dialysis providers and hospital systems using formulary or procurement leverage.

Generic manufacturers may compete through capsule pricing, supply reliability and therapeutic equivalence. Injectable suppliers compete on contract terms, vial configuration, availability and dialysis-center logistics.

Alternative drugs include paricalcitol, calcitriol and other agents used in mineral-bone disorder management. The choice depends on parathyroid hormone control, calcium and phosphorus effects, renal function, route of administration, clinician preference and payer policy.[5]

Product category	Competitive advantage	Excipient opportunity
Doxercalciferol capsule	Low manufacturing complexity and outpatient use	Better uniformity, stability and capsule accessibility
Doxercalciferol injection	Dialysis workflow and direct administration	Improved sterile stability, packaging and ready-to-use presentation
Paricalcitol	Established nephrology use and injectable competition	Limited direct substitution opportunity
Calcitriol	Familiar active metabolite and broad clinical use	Competes on clinical familiarity and price
Oral solution or specialty formulation	Flexible dosing and swallowing benefit	Potential niche differentiation

What FDA regulatory pathway applies to new doxercalciferol formulations?

A conventional generic capsule normally proceeds through an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence to the reference product.[4] A materially different dosage form, route, strength or formulation may require a 505(b)(2) application rather than an ANDA.

ANDA considerations

An ANDA developer should address:

• Active ingredient identity and strength.
• Dosage-form equivalence.
• Dissolution profile.
• Impurity and degradation-product control.
• Content uniformity.
• Stability under ICH conditions.
• Container-closure protection.
• Labeling consistency.
• Therapeutic equivalence requirements.

505(b)(2) considerations

A 505(b)(2) product may be appropriate for:

• An oral solution.
• A new injectable presentation.
• A modified-release product.
• A different capsule shell or excipient system with a clinical advantage.
• A product requiring new clinical or pharmacokinetic evidence.

The pathway can create a differentiated regulatory position, but it usually carries greater development cost and a higher evidence burden than a standard ANDA.

What manufacturing and IP barriers affect commercial entry?

The most important manufacturing barriers are technical rather than molecule-supply barriers.

Oral manufacturing barriers

• Uniform distribution of submicrogram or microgram quantities.
• Avoidance of active loss on equipment surfaces.
• Control of blend segregation.
• Consistent capsule fill weight.
• Protection from light and oxygen.
• Reproducible dissolution after scale-up.

Injectable manufacturing barriers

• Sterile processing or aseptic filling.
• Control of precipitation and particulate formation.
• Container and closure compatibility.
• Protection from light.
• In-use and dilution stability.
• Reliable supply of pharmaceutical-grade solubilizers and surfactants.

IP barriers

A new entrant should map four layers:

1. Orange Book-listed patents.
2. Nonlisted formulation and process patents.
3. Trade secrets involving premix preparation, coating or sterile filling.
4. Regulatory exclusivity connected to any newly approved formulation.

Trade-secret protection may be more important than patent protection for a high-uniformity premix process. A competitor may legally produce an equivalent product through a different process, but process replication can still require substantial development work.

What commercial opportunities exist for doxercalciferol excipients?

The highest-probability opportunities are:

Generic capsule platform

A manufacturer can use a validated low-dose premix and a dual-source excipient system to reduce batch failure and supply interruptions. This is primarily a cost and reliability play.

Dialysis-focused injectable

A ready-to-use or operationally simplified injectable could appeal to dialysis providers if it reduces preparation steps, waste or inventory requirements. Any such product would need a clear stability, handling or workflow advantage.

Patient-accessible dosage form

A hypromellose capsule, oral solution or smaller capsule could target swallowing difficulty, dietary restrictions or dose titration. The market is likely niche but may support premium positioning if reimbursement permits.

Contract manufacturing and private label

The mature product profile supports contract-manufacturing opportunities for regional suppliers, dialysis organizations and specialty generic companies. The differentiator would be validated quality, continuity of supply and flexible packaging rather than clinical innovation.

Excipient supplier opportunity

Excipient suppliers can target:

• Low-moisture diluents.
• Direct-compression grades.
• Flow-enhancing cellulose systems.
• Film or capsule-shell systems with light protection.
• Injectable solubilizers and surfactants.
• Oxygen- and light-barrier packaging.
• Premix manufacturing services.

How strong is the doxercalciferol patent estate?

The estate is weak for the unmodified active ingredient and conventional dosage forms because the product is mature and generic competition exists. It can be moderate for a technically differentiated formulation supported by narrow composition, stability or process claims.

IP layer	Relative strength	Commercial implication
Original active-ingredient protection	Low	Does not create a current barrier to standard generic entry
Conventional capsule formulation	Low	Primarily price competition
Low-dose uniformity process	Moderate	Can protect manufacturing know-how and selected claims
Injectable stability formulation	Moderate	May support differentiated 505(b)(2) development
Packaging and light protection	Low to moderate	Useful as an adjunct, rarely a standalone barrier
Method of use	Low to moderate	Enforcement and prescriber-behavior issues
Trade secrets	Moderate	Can protect process performance without public disclosure

What generic launch scenarios exist?

Immediate price-led entry

Several manufacturers supply equivalent capsules. Prices decline, margins compress and purchasing contracts determine share.

Supply-reliability entry

A new manufacturer captures business by maintaining inventory, qualifying multiple excipient suppliers and reducing back orders. This is particularly relevant for dialysis and hospital customers.

Formulation-differentiated entry

A company launches an oral solution, improved capsule or injectable presentation under a 505(b)(2) or other suitable pathway. The product may command a premium only if the operational or clinical benefit is visible to payers and providers.

Regional or specialty launch

A supplier focuses on dialysis networks, specialty pharmacies or selected international markets. Geographic concentration can reduce launch costs but increases dependence on a small customer base.

How does doxercalciferol compare with competing vitamin D analogs?

Doxercalciferol competes in a treatment area where clinicians balance parathyroid hormone suppression against calcium and phosphorus management. Paricalcitol and calcitriol have stronger recognition in some markets, while doxercalciferol can compete through established use, generic pricing and oral or injectable availability.[5]

The most defensible commercial position is therefore operational: consistent supply, low total treatment cost, suitable dosage strengths and a formulation that performs reliably in dialysis or outpatient workflows.

Key Takeaways

• Doxercalciferol is a mature small-molecule vitamin D analog with generic competition.
• Biosimilar risk does not apply; the relevant regulatory pathway is ANDA, with 505(b)(2) available for differentiated products.
• Excipient strategy should prioritize microgram-dose content uniformity, stability, flow and light protection.
• Injectable opportunities depend on sterility, solubilization, container compatibility and dialysis workflow.
• Original active-ingredient exclusivity is no longer the principal commercial barrier.
• New patent value is most likely in formulation, process, packaging and stability claims.
• The strongest commercial opportunities are generic supply reliability, dialysis-focused injectable products and niche patient-accessible dosage forms.
• A new excipient system is unlikely to support premium pricing without a measurable manufacturing, administration or stability advantage.

FAQs

Can doxercalciferol be reformulated as a tablet?

Yes. A tablet could be developed, but the developer would need to establish dose uniformity, dissolution, stability and bioequivalence. The low dose makes content uniformity the central technical issue.

Is doxercalciferol suitable for a preservative-free injectable?

Potentially. A preservative-free presentation may be attractive for institutional use, but it requires validated sterile manufacturing, container-closure integrity and in-use stability.

Could a new capsule shell support patent protection?

Possibly, but capsule-shell protection alone is usually narrow. Stronger claims would combine the shell with a defined low-dose formulation, stability profile, dissolution result or manufacturing process.

Are excipient patents enough to block a doxercalciferol generic?

Usually not. A generic manufacturer may avoid a claimed excipient combination through a different formulation. Blocking strength depends on claim scope, infringement evidence, validity and regulatory listing status.

Which excipient issue has the greatest effect on manufacturing cost?

Blend uniformity often has the greatest effect because poor distribution of the low-dose active can cause failed batches, additional testing, yield loss and scale-up delays. For injectables, sterile processing and stability failures are the largest cost risks.

References

1. U.S. Food and Drug Administration. (n.d.). Hectorol (doxercalciferol) prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda

3. U.S. National Library of Medicine. (n.d.). Doxercalciferol drug labels and inactive ingredient information. DailyMed. https://dailymed.nlm.nih.gov

4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format. https://www.fda.gov/drugs

5. Kidney Disease: Improving Global Outcomes. (2017). KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder. Kidney International Supplements, 7(1), 1-59.